Region I IPP Infrastructure Updates Advisory Board Meeting June 15, 2010 Boston, MA.

Slides:

Advertisements

Similar presentations

Integrating STD Standards of Care into Family Planning Services: Evaluation of chlamydia screening practices and development of a quality improvement intervention.

Advertisements

Chlamydia Screening Rates among Pregnancy Test Only Visits in Region I, Andee Krasner, MPH Region I IPP Infrastructure.

Assessment of Chlamydia Rescreening Practices Kelly Opdyke, MPH Region II IPP Advisory Committee Mtg May 16-17, 2007 Cicatelli Associates Inc.

How to Measure the Effectiveness of the IPP (and all the CT Screening being done)? **Reduce Infertility** Ultimate Goal Reduce PID Reduce Chlamydia Prevalence.

Impact of a Targeted Provider Intervention to Improve Chlamydia Screening Practices in a Large California Family Planning Program Joan M. Chow 1, MPH,

Revision of Region II IPP Screening Criteria May 16, 2007 Region II IPP Advisory Committee Meeting Cicatelli Associates Inc. New York City.

States, Capitals, and Abbreviations.  This slide show is broken into 3 sections. Each section will have a directions slide before it.  Answer the question.

Epidemiology of Chlamydia in the United States Debra J. Mosure, Ph.D. Division of STD Prevention Centers for Disease Control and Prevention March 8, 2004.

Overview of Gonorrhea (GC) Epidemiology and Program Prevention Efforts.

Chlamydia Sexually Transmitted Disease Surveillance 2000 Division of STD Prevention.

1 Babesia BPAC: FDA Perspective Sanjai Kumar, PhD Division of Emerging and Transfusion- Transmitted Diseases Office of Blood Research and Review CBER,

Appropriate CT/GC Screening & Factors to Consider Becky McCoy MSN, RN, CEN STD Nurse Consultant.

Analysis of Chlamydia Re-testing Rates Massachusetts Family Planning Update.

Infertility Prevention Project Region I June 1, 2009 Wells Beach, Maine Infertility Prevention Project Region I June 1, 2009 Wells Beach, Maine Steven.

EPID Introduction to Analysis and Interpretation of HIV/STD Data Introduction: STDs and HIV—a brief background Manya Magnus, Ph.D. Summer 2001.

STDs in Adolescents and Young Adults Sexually Transmitted Disease Surveillance 2003 Division of STD Prevention.

RTI International is a trade name of Research Triangle Institute Untreated chlamydial infection among adolescents and young adults in Baltimore,

Re-Screening of CT Positive Clients in Region X IPP, Goldenkranz S., 1 Fine D. 1 1 Center for Health Training 2010 CDC STD Prevention Meeting,

HIV/AIDS among Women in Texas Enhanced Perinatal Surveillance May 30, 2007 Nita Ngo, MPH.

Region II Infertility Prevention Project Advisory Committee May 31-June 1, 2006 CDC Update:  Personnel  Budget and Program Changes  Reorganization 

Results from the ACHA Pap Test and STI Survey for Calendar Year 2008 American College Health Association Sexual Health Education and Clinical Care Coalition.

Region I IPP Infrastructure Updates Advisory Board Meeting November 12, 2009 Boston, MA.

Region I IPP Clinic Staff and Provider Assessment Kim Watson, Jennifer Kawatu.

US Virgin Islands IPP: Use of Limited Resources Taetia Phillips-Dorsett, MS Territorial Director, USVI DOH STD/HIV/TB Program Region II IPP Advisory Meeting.

Chlamydial Infections in the U.S. Steven J Shapiro CCID/NCSHHSTP/DSTDP/PTB Region I Infertility Prevention Project Wells Beach, Maine June 2, 2009 Disclaimer:

SSuN: MSM prevalence monitoring and HIV Testing in STD Clinics Kristen Mahle & Lori Newman SSuN Call #3 Oct 30, 2008.

Collecting Site Positivity Data in Region I Andee Krasner, MPH Region I IPP Advisory Board Meeting.

Pilot Study: Re-screening Adolescent and Young Adult Women for Chlamydia Infection Alison Muse NYSDOH Bureau of STD Control Region II IPP meeting November.

IPP Future’s Project Update June 6 and 7, 2011 Region I IPP Advisory Board Meeting.

R Programming Risk & Relative Risk 1. Session 2 Overview 1.Risk 2.Relative Risk 3.Percent Increase/Decrease Risk 2.

Region II IPP Data & Infrastructure Performance Measures Kelly Opdyke, MPH Region II IPP Advisory Committee Mtg May 16-17, 2007 Cicatelli Associates Inc.

NORTHEAST REGION Connecticut ~ Delaware ~ Maine ~ Maryland ~ Massachusetts ~ New Hampshire ~ New Jersey ~ New York ~ Pennsylvania ~ Rhode Island ~ Vermont.

Region I Infertility Prevention Project June 9-10, 2008 Wells Beach, Maine Steven J. Shapiro Infertility Prevention Project Coordinator CDC/CCID/NCHHSTP/DSTDP/PTB.

IPP Measures of Effectiveness Utilization of Data to Evaluate and Inform Project Activities December 12, 2007 Kelly Morrison Opdyke, MPH Region II Infertility.

STDs in Adolescents and Young Adults Sexually Transmitted Disease Surveillance 1998 Division of STD Prevention.

STDs in Adolescents and Young Adults Sexually Transmitted Disease Surveillance 2007 Division of STD Prevention.

Infrastructure Update Jennifer Kawatu Kim Watson Andee Krasner

Targeting Chlamydia Screening Resources Region II IPP Advisory Meeting May 31, 2006 Kelly Opdyke, MPH Cicatelli Associates Inc.

STDs in Adolescents and Young Adults Sexually Transmitted Disease Surveillance 1999 Division of STD Prevention.

STD’s in Adolescents and Young Adults Sexually Transmitted Disease Surveillance 2001 Division of STD Prevention.

New England Colonies By: Carter 5 th grade Mrs. Little.

Region I IPP Data Presentation Advisory Board Meeting June 2008 Wells, ME.

Region I IPP Advisory Board Meeting June 14 and 15, 2010 Wells, ME New Member Orientation An Introduction to the 2010.

STDs in Racial and Ethnic Minorities Sexually Transmitted Disease Surveillance 2003 Division of STD Prevention.

STDs in Women and Infants Sexually Transmitted Disease Surveillance 2007 Division of STD Prevention.

STDs in Adolescents and Young Adults Sexually Transmitted Disease Surveillance 2004 Division of STD Prevention.

Region II Infertility Prevention Project Advisory Committee May 16-17, 2007 New York, New York Steven J. Shapiro Infertility Prevention Project Coordinator.

IPP Infrastructure Measures of Effectiveness: Preliminary Data and Next Steps Kelly Morrison Opdyke, MPH Region II Infertility Prevention Project Cicatelli.

Region I IPP Advisory Board Meeting June 14 and 15, 2010 Wells, ME Chlamydia Testing during Pregnancy Test Only (PTO) Visits.

CONCLUSIONS New Jersey’s Emergency Department HIV testing sites report higher seroprevalence than non-ED testing sites. Since University Hospital began.

What would you like to practice?

States, Capitals, and Abbreviations

Massachusetts’ review

Cost of Screening Outside of IPP Chlamydia Screening Guidelines

HIV Surveillance in Women

States, Capitals, and Abbreviations

Steven J. Shapiro Infertility Prevention Project Coordinator

Region I IPP Data Update Advisory Board Meeting

African Americans and the war

States, Capitals, and Abbreviations

Infertility Prevention Project Coordinator CDC/CCID/NCHHSTP/DSTDP/PTB

For all slides in this series, the following notes apply:

Region I IPP Data Update Region I IPP Advisory Board Meeting

Region I IPP Data Update Region I IPP Advisory Board Meeting

IPP Coordinator’s Update

Region I IPP Data Update Region I IPP Advisory Board Meeting

Our States East of the Mississippi : [Alabama Course of Study Objective1: Locate states, capitals, and important geographic features east of the Mississippi.

Treatment Verification Rates for Chlamydia and Gonorrhea

Gonorrhea Screening: What Do the Data Tell Us?

Presentation transcript:

Region I IPP Infrastructure Updates Advisory Board Meeting June 15, 2010 Boston, MA

Data Overview Positivity Progress towards Regional Goals and Objectives

Chlamydia Positivity in Region I Family Planning Females by Year % Positive

Chlamydia Positivity in Region I Family Planning Females by Year % Positive

Regional Goals and Objectives Objective 1.1 By 2010, increase CT screening by 10% of sexually active year old women and men. Using 2004 data as the baseline, increase from 28,694 to 32,563 in IPP sites.

Objective 1.1

Regional Goals and Objectives Objective 2.2 By 2010, no more than 5% of women more than 25 years of age with no risk factors will be screened in IPP- funded clinics (i.e., 95% will be screened according to regional screening criteria).

Connecticut Risk Factors Family Planning Clinics, Women, 25+ (Objective 2.2: ≥95% screened)

Maine Risk Factors Family Planning Clinics, Women, 25+ (Objective 2.2: ≥95% screened)

Massachusetts Risk Factors Family Planning Clinics, Women, 25+ (Objective 2.2: ≥95% screened)

New Hampshire Risk Factors Family Planning Clinics, Women, 25+ (Objective 2.2: ≥95% screened)

Rhode Island Risk Factors Family Planning Clinics, Women, 25+ (Objective 2.2: ≥95% screened)

Vermont Risk Factors Family Planning Clinics, Women, 25+ (Objective 2.2: ≥95% screened)

Infrastructure Performance Measures Performance Measure 1 –Screening Coverage Estimate Numerator: Number of women screened Denominator: Number of women eligible to be screened

Infrastructure Performance Measures Estimated Screening Coverage by Age Category

Infrastructure Performance Measures –Increased screening in the and age categories over the past 2 years screening rose from 35.6% in 2005 to 45.8% in screening rose from 34.4% in 2005 to 47.4% in 2007 –Decreased screening in females over 24 over the past 2 years Screening >24 went from 40.5% in 2005 to 37.7% in 2007 –Goals Increase the number of women age 24 and under by at least 3% Decrease the number of women age 24+ by at least 3%

Infrastructure Performance Measures Performance Measure 2 –Chlamydia Screening Test Utilization Proportion of total tests given by age category –Numerator: Number of women tested by age category –Denominator: Total number of women tested

Infrastructure Performance Measures Proportion of Female Tests Utilized,

Infrastructure Performance Measures Overview –Very little change over the past 3 years for all 4 age categories Could be a result of budget cuts –Proportion of tests done on women age 29+ is high Could be because data is not broken down by those with and without risk factors, CDC recommends testing age 25+ with risk factors Goal: Increase the proportion of tests utilized by women between the ages of from 0.32 to 0.35 –Decrease the proportion of tests utilized by women 29+ from 0.25 to 0.22

Questions?

Risk Factors Family Planning Clinics, Women, 25+ (Objective 2.2: ≥95% screened)